DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Information source: Novartis
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cystic Fibrosis

Intervention: Tobramycin Inhalation Powder (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Novartis

Summary

Lung infections are a chronic problem for patients with cystic fibrosis (CF). Some patients with CF may have a type of bacteria called Pseudomonas aeruginosa in their lungs that can cause infections or make their symptoms worse. Tobramycin inhalation solution (TOBI) is an approved antibiotic, which is inhaled directly into the lungs, and can be used to manage these infections. Tobramycin inhalation powder (TIP) is a new, experimental powder formulation of tobramycin that is inhaled directly into the lungs using a T-326 inhaler. The purpose of this research study is to determine if TIP is safe and effective when compared to placebo (a powder with no medicine) treatment.

Clinical Details

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study

Primary outcome: Forced expiratory volume in 1 second (FEV1) measured at week 1 and week 5.

Secondary outcome:

Time until first antipseudomonal antibiotic (an antibiotic used to treat bacteria of a certain type [the genus pseudomonas]) is used

Relative changes in FEV1 % predicted for patients who received TIP starting at visit 1 and for patients who received placebo starting at week 9, compared to all subsequent visits.

Relative change in FEV1 % predicted for patients who received placebo from week 5 to week 13

Relative change in FEV1 % predicted for patients who received placebo (from the average of four assessments [weeks 1, 2, 5, and 9] to week 13)

Change from baseline in susceptibility of pseudomonas to the antibiotic during the study measured at weeks 5, 9, 13, 17, 21, and 25, and change from baseline in quantity of pseudomonas found in sputum during the study measured at weeks 5, 9, 13, 17, 21,

Eligibility

Minimum age: 6 Years. Maximum age: 21 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa

infection.

- Male and female subjects between 6 and 21 years of age at the time of screening.

- FEV1 at screening must be between 25% and 80% of normal predicted values.

Exclusion Criteria:

- Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

Locations and Contacts

For information on a site near you, call 1-800-244-7668 Option "2", Buenos Aires, Argentina

For information on a site near you, call 1-800-244-7668 Option "2", Cordoba, Argentina

For information on a site near you, call 1-800-244-7668 Option "2", Varna, Bulgaria

For information on a site near you, call 1-800-244-7668 Option "2", Santiago, Chile

For information on a site near you, call 1-800-244-7668 Option "2", ViƱa del Mar, Chile

For information on a site near you, call 1-800-244-7668 Option "2", Vilnius, Lithuania

For information on a site near you, call 1-800-244-7668 Option "2", Mexico City, Mexico

For information on a site near you, call 1-800-244-7668 Option "2", Tijuana, Mexico

For information on a site near you, call 1-800-244-7668 Option "2", Monterrey, Mexico

For information on a site near you, call 1-800-244-7668 Option "2", Beograd, Serbia and Montenegro

For information on a site near you, call 1-800-244-7668 Option "2", Mobile, Alabama, United States

For information on a site near you, call 1-800-244-7668 Option "2", Phoenix, Arizona, United States

For information on a site near you, call 1-800-244-7668 Option "2", Vancouver, British Columbia, Canada

For information on a site near you, call 1-800-244-7668 Option "2", Fresno, California, United States

For information on a site near you, call 1-800-244-7668 Option "2", Los Angeles, California, United States

For information on a site near you, call 1-800-244-7668 Option "2", Oakland, California, United States

For information on a site near you, call 1-800-244-7668 Option "2", Long Beach, California, United States

For information on a site near you, call 1-800-244-7668 Option "2", Sacramento, California, United States

For information on a site near you, call 1-800-244-7668 Option "2", Pensacola, Florida, United States

For information on a site near you, call 1-800-244-7668 Option "2", Orlando, Florida, United States

For information on a site near you, call 1-800-244-7668 Option "2", Atlanta, Georgia, United States

For information on a site near you, call 1-800-244-7668 Option "2", Augusta, Georgia, United States

For information on a site near you, call 1-800-244-7668 Option "2", Chicago, Illinois, United States

For information on a site near you, call 1-800-244-7668 Option "2", Oak Lawn, Illinois, United States

For information on a site near you, call 1-800-244-7668 Option "2", Ann Arbor, Michigan, United States

For information on a site near you, call 1-800-244-7668 Option "2", Valhalla, New York, United States

For information on a site near you, call 1-800-244-7668 Option "2", New Hyde Park, New York, United States

For information on a site near you, call 1-800-244-7668 Option "2", New York, New York, United States

For information on a site near you, call 1-800-244-7668 Option "2", Durham, North Carolina, United States

For information on a site near you, call 1-800-244-7668 Option "2", Cleveland, Ohio, United States

For information on a site near you, call 1-800-244-7668 Option "2", Columbus, Ohio, United States

For information on a site near you, call 1-800-244-7668 Option "2", Oklahoma City, Oklahoma, United States

For information on a site near you, call 1-800-244-7668 Option "2", Hamilton, Ontario, Canada

For information on a site near you, call 1-800-244-7668 Option "2", Curitiba, PR, Brazil

For information on a site near you, call 1-800-244-7668 Option "2", Philadelphia, Pennsylvania, United States

For information on a site near you, call 1-800-244-7668 Option "2", Sainte-Foy, Quebec, Canada

For information on a site near you, call 1-800-244-7668 Option "2", Florianopolis, SC, Brazil

For information on a site near you, call 1-800-244-7668 Option "2", Campinas, San Paolo, Brazil

For information on a site near you, call 1-800-244-7668 Option "2", Charleston, South Carolina, United States

For information on a site near you, call 1-800-244-7668 Option "2", Tyler, Texas, United States

For information on a site near you, call 1-800-244-7668 Option "2", Salt Lake City, Utah, United States

For information on a site near you, call 1-800-244-7668 Option "2", Morgantown, West Virginia, United States

Additional Information

Click here for more information about the study.

Starting date: September 2005
Ending date: April 2008
Last updated: April 30, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009